- 10:17 PM Where do economists' see Q2 GDP headed?
- 10:04 PM Revealed: Exposure of Indian realty cos to Dubai m...
- 09:59 PM Dubai debt crisis just a trigger, 4500 Nifty key: ...
- 09:16 PM Dubai crisis confirms undue leverage fears: Roubin...
- 08:26 PM Patni promoters to set up a VC fund: Sources
- 08:21 PM November 28-30: Events to watch out for
- 07:27 PM Barclays Bk, Calyon Bk move Bombay HC against Wock...
- 07:17 PM Nirmal Bang's after market report
- 07:13 PM Prestige Group to file DRHP soon: Sources
- 07:11 PM Karnataka govt approves Mittal's Rs 30K cr steel p...



New Delhi May 13
Despite a pre-grant challenge to its Indian patent application due to be heardsoon, the California-based Gilead Sciences is hopeful of making its licence agreements with 10 Indian companies for its HIV drugs, the model for marketing other drugs in the future.
"Making drugs for life threatening diseases available to resource constrained sub-Saharan African countries has been a particular challenge for western companies. We believe that Indian pharma companies with their cost advantage, manufacturing capacities and distribution can help our drugs reach these markets," Mr Gregg Alton, Senior Vice-President and General Counsel, Gilead Sciences told Business Line.
New Model
The agreements entered into since last September cover two drugs, Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate), and allows the Indian partners, which include Aurobindo Pharma, Hetero Drugs, Matrix and Ranbaxy to make any combination of the drugs and more importantly, fix the market price.
Gilead, which gets a five per cent royalty, is hopeful of seeing the Indian drugs reach markets in the next three to six months. If the model is successful, it hopes to replicate it around the world and for other drugs in the future.
Gilead is keen to point out that the agreement with Indian pharma companies also covers technology transfer of the API and the finished antiretrovirals. "The rationale behind multiple partners is to see a high-volume, low-margin business for these drugs," said Mr Alton.
contd on page 2...
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- Dubai crisis: Which Indian companies may be affected
- 10 companies that MF managers love
- Dubai jitters: Will bears overtake investor confidence now?
- Global mkts panic on Dubai's debt rescheduling
- Indian mkts rattled from Dubai default impact

- Mkts singe in Dubai crisis, end down despite smart recovery
- Ganeshaspeaks: Market prediction for Nov 27
- Should you stop picking stocks?
- Ashwani Gujral's top five picks for today's trade

- China`s 50-year bond
Source: ft.com
- Lanco Infra tying up funds for three power projects
Source: Business Line
- RIL units to get 20% of gas needs from D-6
Source: Business Line
- No need to ban cotton export, says Maran
Source: Business Line










